DWC20155
Phase 3Small molecule
Daewoong Pharmaceutical Co. LTD.DWC20155 is one of 21 small molecule programs targeting Gastritis. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Gastritis
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Rabeprazole ER
EisaiApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Mucosta
OtsukaPhase 3
Biaxin
AbbViePhase 2
Entyvio
TakedaPhase 2
Axid
Daewoong Pharmaceutical Co. LTD.Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DWC20155. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details